Par Drugs And Chemicals quarterly results

·UnclassifiedChart ›
Q2 FY27 · Jul–Sep 2026
₹ croreQ2 FY27Q2 FY26Change
Revenue27.428.7−4.3%
EBITDA4.56.1−25.8%
EBITDA margin16.4%21.2%−4.8 pts
Profit before tax3.55.6−36.2%
Net profit2.64.1−36.4%
EPS₹2.14₹3.36−36.3%

Every quarter

₹ crore except per share
Tap a line for its trendQ2 FY27Sep 2026Q1 FY27Jun 2026Q4 FY26Mar 2026Q3 FY26Dec 2025Q2 FY26Sep 2025Q1 FY26Jun 2025Q4 FY25Mar 2025Q3 FY25Dec 2024Q2 FY25Sep 2024Q1 FY25Jun 2024Q4 FY24Mar 2024Q3 FY24Dec 2023Earlier quartersAlpha Plus
27.431.319.629.328.726.022.321.434.722.622.824.0
Earlier quartersEvery year the company has filed comes with Alpha Plus.
0.00.90.41.30.51.80.80.31.00.1−0.00.2
27.432.220.030.729.127.923.121.735.722.722.824.2
Expenses
13.312.88.812.110.511.210.48.910.89.37.28.2
−0.70.90.10.30.20.2−0.7−0.11.2−1.80.1−0.4
1.51.71.91.41.41.41.91.31.41.31.81.4
0.00.00.00.00.10.00.00.00.00.00.00.0
0.91.00.90.90.90.90.90.90.90.90.90.9
8.89.57.39.510.59.78.29.89.89.67.79.5
23.925.919.124.223.623.420.820.924.219.317.719.7
4.56.41.46.16.13.62.41.411.44.26.15.2
3.65.40.55.15.12.71.50.510.53.35.24.4
Profit
3.56.30.86.45.64.52.30.811.53.45.14.6
3.56.30.86.45.64.52.30.811.53.45.14.6
0.91.60.31.61.41.10.60.22.90.91.31.2
0.00.0−0.30.00.00.00.00.00.00.00.00.0
0.91.6−0.01.61.41.10.60.22.90.91.41.2
2.64.70.94.84.13.31.70.68.62.53.73.4
2.64.70.94.84.13.31.70.68.62.53.73.4
2.64.70.94.84.13.31.70.68.62.53.73.4
Per share
₹2.14₹3.83₹0.69₹3.90₹3.36₹2.70₹1.34₹0.47₹6.99₹2.06₹3.02₹2.78
₹2.14₹3.83₹0.69₹3.90₹3.36₹2.70₹1.34₹0.47₹6.99₹2.06₹3.02₹2.78
Per share — as-filed variants
₹2.14₹3.83₹0.69₹3.90₹3.36₹2.70₹1.34₹0.47₹6.99₹2.06₹3.02₹2.78
₹2.14₹3.83₹0.69₹3.90₹3.36₹2.70₹1.34₹0.47₹6.99₹2.06₹3.02₹2.78
Regulatory disclosures — filed alongside, not part of the P&L
1.0—0.8—1.0—1.0—————
Derived — gross profit (revenue − materials − purchases − Δ inventories)
14.817.510.716.917.914.712.612.622.615.115.616.1
54.0%56.1%54.6%57.8%62.6%56.5%56.2%58.8%65.2%66.9%68.2%67.3%
Adjusted (ex-exceptional items) — derived
3.56.30.86.45.64.52.30.811.53.45.14.6
2.64.70.94.84.13.31.70.68.62.53.73.4
₹2.14₹3.83₹0.69₹3.90₹3.36₹2.70₹1.34₹0.47₹6.99₹2.06₹3.02₹2.78
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

PAR₹120.70

Par Drugs And Chemicals Limited

· Unclassified
AnnualQuarterly₹ CrorePeersBALAXICROWNSTEELCITYHINDCONLATTEYSHECPROJECTAIROLAMGROBTEAMcap ₹149 Cr
View
In ₹ Crore except Per Share
3 Months Ending
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Q2 FY27
30/09/2026
Revenue from Operations24.022.822.634.721.422.326.028.729.319.631.327.4
Other Income0.2-0.00.11.00.30.81.80.51.30.40.90.0
Total Income24.222.822.735.721.723.127.929.130.720.032.227.4
Expenses
+ Cost of Materials Consumed8.27.29.310.88.910.411.210.512.18.812.813.3
+ Changes in Inventories-0.40.1-1.81.2-0.1-0.70.20.20.30.10.9-0.7
+ Employee Benefit Expense1.41.81.31.41.31.91.41.41.41.91.71.5
+ Finance Costs0.00.00.00.00.00.00.00.10.00.00.00.0
+ Depreciation & Amortisation0.90.90.90.90.90.90.90.90.90.91.00.9
+ Other Expenses9.57.79.69.89.88.29.710.59.57.39.58.8
Total Expenses19.717.719.324.220.920.823.423.624.219.125.923.9
EBITDA5.26.14.211.41.42.43.66.16.11.46.44.5
EBIT4.45.23.310.50.51.52.75.15.10.55.43.6
Profit
PBT before Exceptional Items4.65.13.411.50.82.34.55.66.40.86.33.5
Pretax Income4.65.13.411.50.82.34.55.66.40.86.33.5
+ Current Tax1.21.30.92.90.20.61.11.41.60.31.60.9
+ Deferred Tax0.00.00.00.00.00.00.00.00.0-0.30.00.0
Tax Expense1.21.40.92.90.20.61.11.41.6-0.01.60.9
Net Income3.43.72.58.60.61.73.34.14.80.94.72.6
+ Net Income — Continuing Ops3.43.72.58.60.61.73.34.14.80.94.72.6
Total Comprehensive Income3.43.72.58.60.61.73.34.14.80.94.72.6
Per Share
Basic EPS2.783.022.066.990.471.342.703.363.900.693.832.14
Diluted EPS2.783.022.066.990.471.342.703.363.900.693.832.14
Per Share — as-filed variants
Basic EPS — Continuing Operations2.783.022.066.990.471.342.703.363.900.693.832.14
Diluted EPS — Continuing Operations2.783.022.066.990.471.342.703.363.900.693.832.14
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period—————1.0—1.0—0.8—1.0
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit16.115.615.122.612.612.614.717.916.910.717.514.8
Gross Margin %67.2768.1966.8865.2158.8056.2156.4862.5857.7654.5756.0653.98
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)4.65.13.411.50.82.34.55.66.40.86.33.5
Net Income Adj (tax-effected)3.43.72.58.60.61.73.34.14.80.94.72.6
EPS Adj2.783.022.066.990.471.342.703.363.900.693.832.14
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.00
Paid Up Equity Capital12.312.312.312.312.312.312.312.312.312.312.312.3
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q2 FY27 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Par Drugs And Chemicals Q2 FY27 results (July–September 2026)

Filed with NSE on Thursday, 29 October 2026 at 5:01 pm IST

Par Drugs And Chemicals (NSE: PAR) reported its Q2 FY27 results (July–September 2026) on Thursday, 29 October 2026 at 5:01 pm IST. Consolidated net profit was ₹2.6 crore, down 36.4% from ₹4.1 crore in Q2 FY26 and down 44.2% from ₹4.7 crore in Q1 FY27. Revenue from operations was ₹27.4 crore, down 4.3% year on year and down 12.3% from the previous quarter.

Q2 FY26 results (a year earlier)
13 November 2025
Q3 FY27 results due by
14 February 2027

Q2 FY27 at a glance · consolidated

Net profit
₹2.6 Cr−36.4% vs Q2 FY26−44.2% vs Q1 FY27
Revenue from operations
₹27.4 Cr−4.3% vs Q2 FY26−12.3% vs Q1 FY27
Operating margin (EBIT)
13.0%−4.9 pts vs Q2 FY26−4.3 pts vs Q1 FY27EBIT ₹3.6 Cr
EBITDA
₹4.5 Cr−25.8% vs Q2 FY26−29.4% vs Q1 FY27margin 16.4%
Earnings per share (basic)
₹2.14−36.3% vs Q2 FY26−44.1% vs Q1 FY27
Net profit margin
9.6%−4.8 pts vs Q2 FY26−5.5 pts vs Q1 FY27

Questions

What was Par Drugs And Chemicals' net profit in Q2 FY27?

Consolidated net profit was ₹2.6 crore, down 36.4% from ₹4.1 crore in Q2 FY26 and down 44.2% from ₹4.7 crore in Q1 FY27.

What was Par Drugs And Chemicals' revenue in Q2 FY27?

Revenue from operations was ₹27.4 crore, down 4.3% year on year and down 12.3% from the previous quarter.

What was Par Drugs And Chemicals' operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹3.6 crore, a margin of 13.0%, against 17.3% in Q1 FY27 and 17.9% in Q2 FY26. EBITDA was ₹4.5 crore, 16.4% of revenue.

How were Par Drugs And Chemicals' Q2 FY27 results?

Both fell from a year earlier: net profit was down 36.4% at ₹2.6 crore and revenue was down 4.3% at ₹27.4 crore. The operating margin was 13.0%, down 4.9 percentage points from 17.9% a year earlier. Against Q1 FY27, net profit was down 44.2% and revenue down 12.3%.

What was Par Drugs And Chemicals' net profit in the first half of FY27?

Consolidated net profit for the first half of FY27 (April–September 2026) was ₹7.3 crore, down 1.6% from ₹7.5 crore in the same months a year earlier. Revenue from operations was ₹58.7 crore, up 7.3%.

What is Par Drugs And Chemicals' net profit margin?

Par Drugs And Chemicals' net profit margin was 9.6% in Q2 FY27 (net profit as a share of revenue from operations), against 14.4% in Q2 FY26 (down 4.8 percentage points). For FY26 as a whole it was 12.6%.

What was Par Drugs And Chemicals' EPS in Q2 FY27?

Basic earnings per share were ₹2.14, against ₹3.36 in Q2 FY26.

What was Par Drugs And Chemicals' net profit in FY26?

Consolidated net profit was ₹13.1 crore in FY26 (April 2025–March 2026), down 1.9% from ₹13.4 crore in FY25. It was ₹14.5 crore in FY24 and ₹11.3 crore in FY23: up 15.7% over three years, 5.0% a year on average.

When did Par Drugs And Chemicals announce its Q2 FY27 results?

On Thursday, 29 October 2026 at 5:01 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 13 November 2025.

How has Par Drugs And Chemicals' profit changed over the last four quarters?

Net profit by quarter: ₹4.8 crore in Q3 FY26, ₹85 lakh in Q4 FY26, ₹4.7 crore in Q1 FY27 and ₹2.6 crore in Q2 FY27. That is ₹13 crore over the four quarters, up 34.1% from ₹9.7 crore in the four quarters before. Revenue from operations: ₹29.3 crore, ₹19.6 crore, ₹31.3 crore and ₹27.4 crore.

What was Par Drugs And Chemicals' revenue in FY26?

Revenue from operations was ₹104 crore in FY26 (April 2025–March 2026), up 2.7% from ₹101 crore in FY25. It was ₹95.6 crore in FY24 and ₹95.7 crore in FY23: up 8.3% over three years, 2.7% a year on average.

When will Par Drugs And Chemicals announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these Par Drugs And Chemicals figures come from?

From Par Drugs And Chemicals' own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 29 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.